| Employment |
| No Relationships to Disclose |
|
|
| Leadership |
| No Relationships to Disclose |
|
|
| Stock and Other Ownership Interests |
| Company: Moderna Therapeutics |
| Recipient: You |
| Company: BioNTech SE |
| Recipient: You |
| Company: Nektar |
| Recipient: You |
|
| Honoraria |
| No Relationships to Disclose |
|
|
| Consulting or Advisory Role |
| Company: Gilead Sciences |
| Recipient: You |
| Company: Pfizer |
| Recipient: You |
| Company: Merck |
| Recipient: You |
| Company: Foundation Medicine |
| Recipient: You |
| Company: Seattle Genetics |
| Recipient: You |
| Company: Bristol-Myers Squibb/Medarex |
| Recipient: You |
| Company: Natera |
| Recipient: You |
| Company: Astellas Pharma |
| Recipient: You |
| Company: Genzyme |
| Recipient: You |
| Company: AstraZeneca |
| Recipient: You |
|
| Speakers' Bureau |
| Company: Bristol-Myers Squibb |
| Recipient: You |
| Company: Gilead Sciences |
| Recipient: You |
| Company: Seattle Genetics |
| Recipient: You |
|
| Research Funding |
| Company: Bristol Myers Squibb Foundation |
| Recipient: Your Institution |
| Company: Merck |
| Recipient: Your Institution |
| Company: Roche/Genentech |
| Recipient: Your Institution |
| Company: EMD Serono |
| Recipient: Your Institution |
| Company: QED Therapeutics |
| Recipient: Your Institution |
| Company: Seattle Genetics |
| Recipient: Your Institution |
| Company: Moderna Therapeutics |
| Recipient: Your Institution |
| Company: Exelixis |
| Recipient: Your Institution |
| Company: Gilead Sciences |
| Recipient: Your Institution |
| Company: Novartis |
| Recipient: Your Institution |
| Company: Tyra Biosciences |
| Recipient: Your Institution |
|
| Patents, Royalties, Other Intellectual Property |
| Please describe: UpToDate author royalty |
| Recipient: You |
|
| Expert Testimony |
| No Relationships to Disclose |
|
|
| Travel, Accommodations, Expenses |
| Company: Pfizer |
| Recipient: You |
|
| Other Relationship |
| No Relationships to Disclose |
|
|
| (OPTIONAL) Uncompensated Relationships |
| No Relationships to Disclose |
|
|
| (OPTIONAL) Open Payments Link |
| not answered |
|
|